...Chiara Gastaldon; Emanuel Raschi; John M. Kane; Corrado Barbui; Georgios Schoretsanitis Introduction: Esketamine nasal spray received approval for treatment-resistant depression in March 2019. Objective: Using the FDA Adverse Event Reporting System (FAERS) database (March 2019–March 2020), we...

... infusion therapy for treatment-resistant depression were invited to participate in the study. If enrolled, the subjects initiated a 12-session, 10-week course of CBT concurrently with a short 4-treatment, 2-week course of intravenous ketamine (0.5 mg/kg infused over 40 min) provided under a standardized...

...Stuart J. Eisendrath; Erin Gillung; Kevin L. Delucchi; Zindel V. Segal; J. Craig Nelson; L. Alison McInnes; Daniel H. Mathalon; Mitchell D. Feldman Background: Due to the clinical challenges of treatment-resistant depression (TRD), we evaluated the efficacy of mindfulness-based cognitive therapy...

... to treatment-resistant depression (TRD). Results: Switching to a different antidepressant is a useful option following nonresponse to a first-line agent. Although widely used in clinical practice, there is limited evidence to support antidepressant combination for TRD. Notwithstanding evidence for lithium or T...

... treatment Treatment continuation Treatment-resistant depression Antidepressant-resistant depression Antidepressive agents Depression relapse When medications are evaluated to determine their applicability to evidence-based clinical practice, it is important to assess their efficacy...

... of this study was to compare the prevalence of Axis II disorders between a sample of rigorously defined, treatment-resistant depressed outpatients and a sample of depressed outpatients not having experienced treatment resistance. Methods: 53 patients with treatment-resistant depression (TRD) and 105 patients...